Paper Details

  1. Home
  2. Paper Details

Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial.

Author: CombalbertJean, DepypereHerman, DondersGilbert, FraserGraeme L, HoveydaHamid R, RamaelSteven, SieprathPeter, TimmermanDirk

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Fezolinetant, a neurokinin 3 receptor (NK3R) antagonist, significantly reduced moderate/severe vasomotor symptoms (VMSs) in menopausal women. The drug demonstrated a rapid and significant reduction in VMSs from the first day of treatment and was well tolerated.
Paper Details　
Original Abstract of the Article :
CONTEXT: The thermoregulatory center in the hypothalamus is stimulated by neurokinin 3 receptor (NK3R) activation and inhibited by estrogen-negative feedback. This balance is disrupted in menopause, producing vasomotor symptoms (VMSs). OBJECTIVE: To evaluate safety and efficacy of the NK3R antagoni...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1210/jc.2019-00677

データ提供：米国国立医学図書館（NLM）

Fezolinetant: A Promising Treatment for Menopausal Vasomotor Symptoms

This research investigates the effectiveness of fezolinetant, a neurokinin 3 receptor antagonist, in treating menopausal vasomotor symptoms (VMSs). VMSs are common in women going through menopause and can significantly impact their quality of life. This study explores the potential of fezolinetant as a non-hormonal treatment option for VMSs. The study found that fezolinetant was effective in reducing the frequency and severity of VMSs, and it was well tolerated by patients.

Fezolinetant: A Potential Non-Hormonal Solution for VMSs

This study offers encouraging evidence for the effectiveness of fezolinetant in treating menopausal vasomotor symptoms. The researchers' findings demonstrate that fezolinetant can significantly reduce the frequency and severity of VMSs, offering a potential non-hormonal treatment option for women experiencing these uncomfortable symptoms. This research provides a glimmer of hope for women seeking relief from VMSs.

Implications for Menopausal Health and Well-being

This research highlights the potential of fezolinetant as a valuable treatment option for menopausal women experiencing vasomotor symptoms. The study emphasizes the need for effective non-hormonal treatments to address this common and often challenging condition. This research could lead to improved treatment options for menopausal women, enhancing their quality of life and well-being.

Dr.Camel's Conclusion

This study is like finding a cool oasis in the midst of the hormonal desert that many women experience during menopause. Fezolinetant offers a refreshing and potentially effective non-hormonal treatment option, providing a new path to relief for women seeking to manage the discomfort of vasomotor symptoms.

Date :
  1. Date Completed 2020-06-04
  2. Date Revised 2020-06-04
Further Info :

Pubmed ID

31415087

DOI: Digital Object Identifier

10.1210/jc.2019-00677

Related Literature

Article Analysis
・Effects of fezolinetant
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.